List of Excipients in Branded Drug QSYMIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vivus Inc	QSYMIA	phentermine and topiramate	62541-201	CELLULOSE, MICROCRYSTALLINE
Vivus Inc	QSYMIA	phentermine and topiramate	62541-201	ETHYLCELLULOSE
Vivus Inc	QSYMIA	phentermine and topiramate	62541-201	FD&C BLUE NO. 1
Vivus Inc	QSYMIA	phentermine and topiramate	62541-201	FD&C RED NO. 3

Last updated: August 7, 2026

Qsymia is an extended-release combination of phentermine hydrochloride and topiramate designed to deliver immediate-release phentermine with extended-release topiramate. Its excipient system is commercially attractive because generic, 505(b)(2), and lifecycle-development opportunities can target multiparticulate release, capsule technology, dose flexibility, manufacturability, and risk-management requirements. The main constraints are bioequivalence, topiramate’s teratogenicity, Qsymia’s REMS history, and patent claims covering the combination and obesity-treatment methods.

Qsymia Excipient Strategy and Commercial Opportunities

What is Qsymia and how does its dosage form work?

Qsymia is an oral, once-daily, extended-release capsule containing phentermine hydrochloride and topiramate. The product is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and certain adolescents with obesity or overweight plus a weight-related condition.[1]

The approved strengths are:

Qsymia strength	Phentermine HCl	Topiramate
3.75 mg/23 mg	3.75 mg	23 mg
7.5 mg/46 mg	7.5 mg	46 mg
11.25 mg/69 mg	11.25 mg	69 mg
15 mg/92 mg	15 mg	92 mg

The product uses two pharmacologically different release profiles:

• Phentermine is delivered for relatively rapid systemic exposure.
• Topiramate is released in an extended manner to support once-daily dosing and manage exposure over the dosing interval.

The formulation therefore requires more than simple powder blending. A viable equivalent must control content uniformity across low-dose phentermine, maintain topiramate release, protect physical stability, and reproduce the pharmacokinetic relationship between the two active ingredients.

What excipients are used in Qsymia?

The Qsymia prescribing information identifies a conventional solid-dose excipient platform that includes microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, talc, gelatin, titanium dioxide, colorants, and printing components.[1]

Excipient or material	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Diluent, pellet or granule matrix, compression aid	High-volume commodity with opportunities for grade optimization
Povidone	Binder and processing aid	Supplier differentiation through molecular weight, viscosity, and low-peroxide grades
Sodium lauryl sulfate	Wetting and dissolution aid	Useful for improving powder wetting and dispersion of poorly wettable components
Magnesium stearate	Lubricant	Lubrication level can affect dissolution, blend uniformity, and capsule performance
Talc	Glidant or anti-adherent	Particle-size and purity controls affect flow and processing
Gelatin	Capsule shell	Opportunities exist in shell color, moisture control, and non-gelatin alternatives
Titanium dioxide and colorants	Capsule identification and product differentiation	Relevant to strength-specific color coding and regulatory changes
Printing ink components	Product identification	Supports dose-strength differentiation and serialization

The public label identifies the excipient categories, but it does not establish the complete commercial bill of materials, supplier identities, particle-size distributions, coating process parameters, or critical material attributes. Those manufacturing details are likely to be more valuable than the basic excipient list for competitive development.

Which excipients create the strongest commercial opportunities?

Microcrystalline cellulose and functional fillers

Microcrystalline cellulose is the most obvious platform opportunity. A supplier can pursue:

• High-flow grades for capsule filling.
• Low-moisture grades for improved stability.
• Co-processed cellulose systems for blend uniformity.
• Grades optimized for multiparticulate coating.
• Narrow particle-size distributions to reduce segregation between phentermine and topiramate components.

The commercial value is greatest where a new grade solves a measurable manufacturing problem. A generic developer is more likely to change the filler system if the change improves content uniformity, reduces compression or filling variability, or simplifies scale-up without altering dissolution.

Povidone and binder systems

Povidone can influence granule strength, drug distribution, residual moisture, and dissolution. Low-peroxide or controlled-impurity grades may be relevant because oxidation-sensitive active ingredients and long-term stability requirements can restrict excipient selection.

A supplier could differentiate through:

• Low-peroxide povidone.
• Controlled viscosity grades.
• Granulation systems that reduce overbinding.
• Co-processed binders for direct filling or compression.
• Documentation packages supporting extractables, elemental impurities, and nitrosamine assessments.

Surfactants and wetting agents

Sodium lauryl sulfate is a low-cost material, but its concentration and distribution can affect dissolution and gastrointestinal tolerability. A replacement or reduced-level surfactant strategy could be commercially relevant if it preserves dissolution while reducing variability or improving patient acceptability.

Potential alternatives include poloxamers, sodium stearyl fumarate in selected applications, or other pharmacopeial wetting systems. Any substitution would require comparative dissolution and bioequivalence work because the active ingredients have different release requirements.

Capsule shells and coatings

Capsule technology is a significant opportunity because Qsymia uses multiple dose strengths with color differentiation. Opportunities include:

• Moisture-controlled hard gelatin capsules.
• Hypromellose capsules.
• Plant-based capsule systems.
• Improved opacity and color matching.
• Low-fragility shells for high-speed filling.
• Tamper-evident and serialization-compatible printing systems.

A hypromellose capsule could support a differentiated 505(b)(2) product or a reformulation, but it would introduce new moisture, dissolution, and shell-performance variables. For an ANDA, capsule-shell substitution must preserve product performance and meet the relevant inactive-ingredient and bioequivalence requirements.

What formulations are protected by Qsymia-related intellectual property?

Qsymia-related intellectual property has historically covered the combination of phentermine and topiramate, dosage regimens, extended-release delivery, and methods for treating obesity. The commercial risk is not limited to the presence of the two active ingredients. A proposed product can encounter claims directed to:

• Specific phentermine-to-topiramate dose ratios.
• Once-daily administration.
• Extended-release topiramate in combination with immediate-release phentermine.
• Treatment of patients with obesity or overweight.
• Dose titration and escalation.
• Safety-related treatment conditions.

The key formulation distinction is the release profile. A product that contains the same ingredients but releases both immediately may avoid some formulation claims while creating clinical and regulatory problems. A product that reproduces the Qsymia profile more closely may face greater freedom-to-operate exposure.

Patent analysis should separate:

1. Composition claims.
2. Multiparticulate or coated-particle claims.
3. Method-of-treatment claims.
4. Dose-escalation claims.
5. Manufacturing claims.
6. Regulatory exclusivity and Orange Book-listed patents.

FDA Orange Book listings and USPTO records should be reviewed together because listed patent status, terminal disclaimers, PTA, litigation outcomes, and delisting events can affect actual launch risk.[2,3]

When did Qsymia lose regulatory exclusivity?

Qsymia received FDA approval on July 17, 2012.[4] Its five-year new chemical entity exclusivity period did not create a permanent barrier to abbreviated applications. The product’s longer commercial protection has depended primarily on patent rights, regulatory requirements, product complexity, and the economics of developing an equivalent extended-release combination.

Qsymia also carries important safety controls. Topiramate exposure is associated with fetal harm, including oral clefts, and the product labeling includes pregnancy testing and contraception requirements for women of reproductive potential.[1] Qsymia was subject to a Risk Evaluation and Mitigation Strategy involving prescriber, pharmacy, and patient controls. The FDA later determined that the REMS was no longer required for Qsymia, while retaining labeling requirements related to pregnancy prevention and fetal-risk counseling.[5]

The end of regulatory exclusivity does not automatically produce generic entry. A challenger still must establish pharmaceutical equivalence, bioequivalence, acceptable labeling, manufacturing compliance, and a legally supportable patent position.

What is the Orange Book status of Qsymia?

Qsymia is an FDA-approved prescription drug listed in the Orange Book. The relevant analytical questions are:

• Which patents remain listed?
• Which claims cover the proposed generic product?
• Are any listed patents method-of-use patents that can be carved out?
• Do the patents expire before or after the expected ANDA review period?
• Are there terminal disclaimers or patent-term adjustments?
• Has a Paragraph IV notice triggered litigation?

A generic applicant must certify against listed patents under the Hatch-Waxman framework. A Paragraph IV certification asserts that a patent is invalid, unenforceable, or will not be infringed. If the patent holder files suit within the statutory period after receiving notice, FDA approval can be delayed by the statutory 30-month stay unless the litigation is resolved earlier or the stay is otherwise altered.[6]

The practical barrier for Qsymia is likely to be the combined need to match release behavior and defend a patent position. A formulation that is clearly different may reduce infringement exposure but increase bioequivalence risk. A formulation that closely mirrors the reference product may improve regulatory feasibility while narrowing design-around options.

Which generic-entry scenarios exist for Qsymia?

Scenario 1: Conventional ANDA with close formulation matching

This is the most direct pathway. The applicant would reproduce the reference product’s essential release behavior using equivalent or functionally similar excipients.

Advantages include:

• Clearer pharmaceutical-equivalence strategy.
• Lower clinical development burden than a novel formulation.
• Stronger precedent for matching an established capsule product.

Risks include:

• Patent claims directed to release characteristics or dose combinations.
• Difficulty demonstrating bioequivalence with low-dose phentermine.
• Blend segregation and content-uniformity problems.
• Potential litigation after Paragraph IV certification.

Scenario 2: Design-around extended-release formulation

The applicant could use different polymers, coated beads, matrix particles, or capsule components.

Advantages include:

• Potential reduction in infringement risk.
• Opportunity to improve stability, manufacturing yield, or capsule performance.
• Possibility of securing new formulation patents.

Risks include:

• Greater formulation-development cost.
• More complex dissolution method development.
• Higher likelihood of pharmacokinetic divergence.
• Potential need for additional clinical or bridging evidence.

Scenario 3: 505(b)(2) reformulation

A 505(b)(2) product could target a different delivery format, such as a sprinkle capsule, modified-release tablet, or alternative capsule shell. The opportunity would be strongest where the product offers a clinically relevant advantage, including easier administration or improved dose titration.

A 505(b)(2) strategy is less attractive if the product provides no meaningful benefit over Qsymia and could face patent certifications, labeling disputes, or limited payer differentiation.

How can excipients improve Qsymia’s commercial positioning?

Better dose titration

Qsymia already uses four strengths. An excipient-enabled multiparticulate system could support more flexible dose increments without adding multiple capsules. This could be valuable for patients who cannot tolerate rapid escalation.

A commercial product could use:

• Divisible multiparticulate fills.
• Bead-in-capsule systems.
• Sachets or sprinkle capsules.
• Unit-dose titration packs.

Dose flexibility must preserve the required phentermine and topiramate exposure relationship. It cannot be treated as a simple tablet-splitting problem.

Improved administration

A sprinkle formulation could address patients who have difficulty swallowing capsules. The particles would need to maintain release properties when administered with soft food or another approved vehicle. The formulation would also require tight control of coating integrity, taste, dose recovery, and stability after opening.

Improved manufacturing economics

The most immediate commercial opportunity may be process optimization rather than a new dosage form. High-flow excipients, improved lubrication, narrower particle-size distributions, and lower-dust materials could reduce:

• Capsule-filling rejects.
• Blend segregation.
• Weight variability.
• Cleaning time.
• Coating defects.
• Operator exposure to active pharmaceutical ingredients.

These improvements can support contract-manufacturing opportunities even where the finished product remains legally similar to Qsymia.

Reduced excipient risk

A replacement excipient system could target:

• Lower peroxide burden.
• Lower elemental impurity risk.
• Improved moisture control.
• Reduced nitrosamine concern.
• Better global regulatory acceptance.
• Elimination of colorants that face regional restrictions.

A global formulation may need different capsule shells or color systems across jurisdictions. Excipients with broad compendial acceptance reduce regulatory fragmentation.

What manufacturing and IP barriers affect excipient suppliers?

Excipient suppliers face a different competitive position from generic drug applicants. A supplier’s material may be unpatented, but its application in a specific Qsymia-like formulation may be captured by formulation or process claims.

Commercial barriers include:

• Drug-master-file qualification.
• Change-control obligations.
• Supply continuity requirements.
• Particle-size and moisture specifications.
• Customer validation costs.
• Regional pharmacopeial differences.
• Confidential process knowledge held by the reference sponsor or contract manufacturer.

The strongest supplier strategy is to patent a functional excipient system or process improvement rather than merely claim a known excipient in a known capsule. Examples include a controlled-release particle platform, a low-peroxide binder system, or a co-processed carrier that improves phentermine uniformity while preserving topiramate release.

How does Qsymia compare with competing obesity drugs?

Qsymia competes with injectable GLP-1 and GIP/GLP-1 products, oral anti-obesity medicines, and generic or low-cost off-label therapies. Its principal commercial advantages are oral administration, dose titration, and established labeling. Its disadvantages include teratogenicity controls, sympathomimetic exposure, central nervous system adverse effects, and a more complex safety-management profile than many patients expect from an oral capsule.

Product category	Formulation opportunity	Main commercial constraint
Qsymia-like combination	Multiparticulate capsule, dose packs, sprinkle delivery	Patent, bioequivalence, topiramate pregnancy risk
GLP-1 injectables	Pen devices, depot systems, stabilizing excipients	Injectable manufacturing and device complexity
Oral GLP-1 products	Absorption enhancers and protective coatings	Low oral bioavailability and formulation sensitivity
Naltrexone/bupropion products	Modified-release matrix systems	CNS and blood-pressure tolerability
Orlistat products	Lipid-compatible capsules and excipient systems	Gastrointestinal adverse effects and adherence

Qsymia’s excipient opportunities are therefore most credible in oral delivery, dose titration, and manufacturing efficiency rather than in direct competition with long-acting injectable exposure profiles.

What licensing opportunities exist around Qsymia excipients?

Potential licensing targets include:

• Multiparticulate controlled-release platforms.
• Capsule-shell technologies with improved moisture control.
• Co-processed excipients for low-dose blend uniformity.
• Taste-masking systems for sprinkle administration.
• Formulations that enable smaller or more flexible dose increments.
• Manufacturing processes that reduce coating time or improve yield.

A licensing agreement could be structured around an excipient platform, a finished dosage form, or a regional commercialization right. The strongest diligence points are ownership of background patents, freedom to operate against Qsymia patents, regulatory precedent for the excipients, and whether the technology creates a measurable clinical or manufacturing advantage.

What is the revenue exposure and market opportunity?

Qsymia’s commercial opportunity is tied to the expanding obesity-treatment market, but revenue capture depends on payer coverage, competition from injectable therapies, and generic-entry timing. The product’s oral format creates a lower-cost development and manufacturing pathway than complex biologics, but the combination’s safety profile limits broad substitution by a simple low-cost capsule.

The highest-value opportunities are:

1. A legally defensible generic with reliable bioequivalence.
2. A dose-flexible formulation that improves titration.
3. A sprinkle or swallow-friendly product with a clear patient benefit.
4. Excipient and process platforms that reduce manufacturing cost.
5. Regional licensing of an improved oral obesity product.

Key Takeaways

• Qsymia combines immediate-release phentermine with extended-release topiramate in a once-daily capsule.
• Its disclosed excipient system includes microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, talc, gelatin, titanium dioxide, colorants, and printing materials.
• The most attractive excipient opportunities involve blend uniformity, multiparticulate release, capsule-shell performance, moisture control, and dose flexibility.
• Generic developers face a combined formulation and patent challenge. Matching Qsymia improves bioequivalence prospects but can increase infringement exposure.
• A 505(b)(2) product could pursue sprinkle delivery, alternative capsule shells, or flexible titration, but it would need a defensible clinical or pharmaceutical advantage.
• Topiramate’s fetal-risk profile remains a central regulatory and commercial constraint.
• Excipient suppliers can create stronger positions by patenting functional systems and manufacturing improvements rather than selling undifferentiated commodity materials.

FAQs

Can Qsymia be reformulated as a tablet?

Yes. A tablet could use separate immediate-release and extended-release layers or multiparticulate compartments, but the release relationship between phentermine and topiramate would need to remain clinically appropriate.

Could a generic Qsymia use different excipients?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, but the substitute excipients must support pharmaceutical equivalence, bioequivalence, stability, and acceptable labeling.

Is a sprinkle version of Qsymia commercially viable?

Potentially. A sprinkle version could address swallowing difficulty and improve dose administration, but coated-particle integrity, taste, dose recovery, and food compatibility would be critical development issues.

Do Qsymia excipients determine patent infringement?

Usually not by themselves. Infringement risk depends on the wording of issued claims and how the proposed product practices composition, release, dosage, treatment, or manufacturing limitations.

Which excipient has the highest strategic value in a Qsymia generic?

The highest strategic value is likely to come from the functional combination of filler, binder, surfactant, and release-controlling materials. No single commodity excipient is likely to determine commercial success.

References

1. U.S. Food and Drug Administration. (2024). Qsymia (phentermine and topiramate extended-release) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System.
4. U.S. Food and Drug Administration. (2012, July 17). FDA approves weight-management drug Qsymia.
5. U.S. Food and Drug Administration. (2023). Qsymia REMS modification and safety information.
6. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity for generic drug products.